Comparison of rivaroxaban – an oral, direct factor Xa inhibitor – and subcutaneous enoxaparin for thromboprophylaxis after total knee replacement (RECORD4: a phase 3 study)European Federation of National Associations of Orthopaedics and Traumatology (EFFORT) 2008 Annual Meeting; May 29–June 1, - Turpie, A; Bauer, K; Davidson, B (2008)
Nice, France. Abstract F85.